Home LiteratureArticle Details
PMID: 41998173 Published · epublish English

The contributions of TLR2, TLR8 and TLR3 to direct and antibody-dependent enhancement of dengue virus serotype 2 infection.

Npj viruses ·Vol. 4 ·No. 1 ·2026-04-17

Ter Ellen BM, Punekar M, Castillo JA, Valdés-López JF, Upasani V, Sann S, Karnthaler M, Martija B, Moser J, Smit JM, Cantaert T, Rodenhuis-Zybert IA

Abstract

Antibody-dependent enhancement (ADE) of dengue virus-type 2 (DENV2) is a major risk factor for severe disease, facilitating Fcγ receptor-mediated viral entry and triggering inflammation that compromises vascular integrity. While Toll-like receptor 2 (TLR2) on monocytes promotes DENV2, strain 16681 infection in these cells and triggers an inflammatory response that activates the endothelium, its contribution to ADE remains unclear. Here, using peripheral blood mononuclear cells, we compared FcγRII (CD32)-mediated ADE infection with direct infection and assessed the contributions of TLR2, RNA sensors (TLR8, TLR3), and spleen tyrosine kinase (SYK). Blocking CD32 or SYK reduced antibody-enhanced infection to direct infection levels, whereas TLR2 inhibition abolished infection entirely. Furthermore, TLR8, TLR3, and SYK mediated inflammatory responses under both ADE and direct infection. These findings identify TLR2 as indispensable also for CD32/SYK-driven viral entry and implicate TLR8, TLR3, and SYK in ADE-associated inflammation. Our study provides mechanistic insight into ADE pathogenesis and highlights potential targets for mitigating severe dengue outcomes.

Article Info
Journal
Npj viruses
Abbr.
Npj Viruses
ISSN
2948-1767
Published
2026-04-17
Language
English
Country/Region
England
NLM ID
9918716188906676
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]